Trials / Completed
CompletedNCT01810666
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
Routine Prophylaxis Treatment Versus On-demand Treatment for Children With Severe Hemophilia A: Comparison of All Bleeding Events in Chinese Hemophilia Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 2 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of the effect of three times a week prophylaxis on all bleeds with on-demand treatment for children with severe Hemophilia A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care. |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2013-03-13
- Last updated
- 2015-05-19
- Results posted
- 2015-01-05
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01810666. Inclusion in this directory is not an endorsement.